Healthcare

Keensight Capital Acquires Majority Stake in Isto Biologics, a Leading Orthobiologics Player, from Thompson Street Capital Partners

Keensight Capital ("Keensight"), one of the leading private equity managers dedicated to pan-European Growth Buyout investments, today announced it has...

Aspire Biopharma Engages Well-Known Athletes and Influencers to Accelerate Consumer Awareness and Sales of its BUZZ BOMB(TM) Sublingual Caffeine Pre-Workout Product

BUZZ BOMB™ engages three specialized fitness influencers to grow the brandhttps://www.instagram.com/bobbymaximus/https://www.instagram.com/midwest_kong/https://www.instagram.com/ifbbpro_moose_the_stallion/The influencers have hundreds of thousands of followers across social...

Protagonist Announces Presentations of Clinical Data with Icotrokinra in Plaque Psoriasis and Preclinical Data with PN-881 at the EADV 2025 Congress

Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event rates to placebo...

PolyPid to Present at Lytham Partners Fall 2025 Investor Conference and Participate in 4th Annual ROTH Healthcare Opportunities Conference

PETACH TIKVA, Israel, Sept. 17, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company...

New York State Medicaid Expands Coverage for TMS Therapy, Including NeuroStar® Advanced Therapy, to Treat Major Depressive Disorder (MDD)

Over 5 million New York Medicaid members to gain access to Transcranial Magnetic Stimulation (TMS) servicesMALVERN, Pa., Sept. 17, 2025...

Regeneron Announces Positive Phase 3 Trial in Adults with Ultra-Rare Genetic Disorder Fibrodysplasia Ossificans Progressiva (FOP), Demonstrating that Garetosmab Prevents Greater than 99% of Abnormal Bone Formation

TRUE-See Announces Strategic Partnership with Dr. Peter Chang and the Center for Applied AI Research at the University of California, Irvine

TRUE-See Expands Its AI Clinical Leadership Capabilities with Addition of Dr. Peter Chang as Senior AI AdvisorNEW ORLEANS, Sept. 17,...

AccuStem Sciences and EmeritusDX Expand Blood-Based Testing Capabilities to Advance Cancer Diagnostics and Treatment Planning

PHOENIX, Ariz. and LONDON, Sept. 17, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company...

error: Content is protected !!